Covered recipient · General Payments record
NAKHLE S SABA
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$187,661.80
203 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $107,260.00 | 32 |
| Consulting Fee | $49,935.00 | 12 |
| Travel and Lodging | $26,606.70 | 97 |
| Food and Beverage | $3,780.11 | 61 |
| Education | $79.99 | 1 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Pharmacyclics LLC, an AbbVie Company | $71,500.90 | 95 |
| ABBVIE INC. | $40,196.47 | 40 |
| Janssen Biotech, Inc. | $27,351.09 | 19 |
| ADC Therapeutics America, Inc. | $25,340.02 | 15 |
| Seagen Inc. | $10,045.01 | 11 |
| Eli Lilly and Company | $6,300.00 | 1 |
| Incyte Corporation | $4,769.93 | 8 |
| Genentech USA, Inc. | $1,650.00 | 1 |
| BeiGene USA, Inc. | $277.36 | 4 |
| Takeda Pharmaceuticals U.S.A., Inc. | $79.99 | 1 |
| Amgen Inc. | $56.52 | 3 |
| Celgene Corporation | $36.54 | 2 |
| Acrotech Biopharma LLC | $22.07 | 1 |
| Astellas Pharma US Inc | $21.73 | 1 |
| Exelixis Inc. | $14.17 | 1 |
Page 2 of 5; records 51–100 of 203 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
NAKHLE S SABA
NPI 1275714669 · CMS profile ID 1297710
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
BATON ROUGE, LA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 5; records 51–100 of 203 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1275714669?year=2022&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- NAKHLE S SABA, NPI 1275714669, CMS profile ID 1297710. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 203 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275714669?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). NAKHLE S SABA, NPI 1275714669, CMS profile ID 1297710. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 203 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275714669?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- NAKHLE S SABA, NPI 1275714669, CMS profile ID 1297710, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 203 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1275714669?year=2022&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
203 matching records · $187,661.80 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 203.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $116.10 | 10/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891498347 | CMS |
| Seagen Inc. | $8,415.00 | 09/30/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 904118935 | CMS |
| BeiGene USA, Inc. | $15.19 | 09/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940796353 | CMS |
| BeiGene USA, Inc. | $121.47 | 09/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940796355 | CMS |
| Seagen Inc. | $180.00 | 09/13/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 904118947 | CMS |
| Seagen Inc. | $140.00 | 09/13/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 904118949 | CMS |
| Seagen Inc. | $496.92 | 09/10/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 904118941 | CMS |
| Seagen Inc. | $64.85 | 09/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 904118943 | CMS |
| Seagen Inc. | $18.21 | 09/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 904118951 | CMS |
| Seagen Inc. | $64.85 | 09/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 904118969 | CMS |
| Seagen Inc. | $120.29 | 09/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 904118945 | CMS |
| Seagen Inc. | $353.96 | 08/30/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 904118939 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $4,100.00 | 08/29/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890346817 | CMS |
| BeiGene USA, Inc. | $15.70 | 08/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940796357 | CMS |
| ADC Therapeutics America, Inc. | $276.64 | 08/20/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 922062951 | CMS |
| ADC Therapeutics America, Inc. | $392.68 | 08/20/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 922062953 | CMS |
| ADC Therapeutics America, Inc. | $157.14 | 08/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 922062955 | CMS |
| ADC Therapeutics America, Inc. | $110.29 | 08/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 922062961 | CMS |
| ABBVIE INC. | $54.01 | 08/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891498341 | CMS |
| ABBVIE INC. | $50.75 | 08/18/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891498343 | CMS |
| Exelixis Inc. | $14.17 | 08/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932465235 | CMS |
| Janssen Biotech, Inc. | $2,525.00 | 08/12/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885963623 | CMS |
| ABBVIE INC. | $70.91 | 08/09/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891498337 | CMS |
| ABBVIE INC. | $32.52 | 08/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891498339 | CMS |
| Janssen Biotech, Inc. | $1,262.50 | 08/09/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 886748377 | CMS |
| ADC Therapeutics America, Inc. | $1,460.00 | 08/04/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 922062911 | CMS |
| ABBVIE INC. | $4,725.00 | 08/03/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891498335 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $195.00 | 08/02/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890346809 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $367.51 | 08/02/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890346811 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $124.98 | 08/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890346813 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $693.71 | 08/02/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890346815 | CMS |
| ABBVIE INC. | $253.20 | 07/26/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891498331 | CMS |
| ABBVIE INC. | $482.13 | 07/26/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891498333 | CMS |
| Janssen Biotech, Inc. | $4,100.00 | 07/26/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885963611 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $682.52 | 07/26/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890346771 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $258.01 | 07/26/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890346773 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $311.90 | 07/26/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890346775 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $157.08 | 07/26/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890346777 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $2,050.00 | 07/26/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890346779 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $11.00 | 07/26/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890346781 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $231.80 | 07/26/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890346783 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $20.93 | 07/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890346785 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $6.00 | 07/26/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890346787 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $6.00 | 07/26/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890346789 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $28.75 | 07/26/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890346791 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $30.00 | 07/26/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890346793 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $4,100.00 | 07/26/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890346795 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $108.75 | 07/26/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890346797 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $149.00 | 07/26/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890346799 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $149.00 | 07/26/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890346801 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $50,085.00 | 12 |
| PY2024 | Recipient | $1,232.74 | 2 |
| PY2024 | Principal investigator | $199,296.45 | 22 |
| PY2023 | Principal investigator | $541,315.58 | 62 |
| PY2022 | Recipient | $40.00 | 1 |
| PY2022 | Principal investigator | $379,003.27 | 47 |
| PY2021 | Principal investigator | $171,422.95 | 48 |
| PY2020 | Principal investigator | $146,109.61 | 28 |
| PY2019 | Principal investigator | $115,093.98 | 47 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
12 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Incyte Corporation | $1,300.00 | 12/01/2025 | Covered Recipient Teaching Hospital Tulane Medical Center | realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (realMIND) | No dispute reported | 06/30/2026 | 1240489635 |
| Principal investigator 1 | Incyte Corporation | $2,380.00 | 12/01/2025 | Covered Recipient Teaching Hospital Tulane Medical Center | realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL (realMIND) | No dispute reported | 06/30/2026 | 1240489641 |
| Principal investigator 1 | Eli Lilly and Company | $3,520.05 | 10/22/2025 | Non-covered Recipient Entity THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | STUDY OF LOXO-305 VERSUS INVESTIGATOR'S CHOICE (IDELAR OR BR) IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) (BRUIN CLL-321) | No dispute reported | 06/30/2026 | 1187892812 |
| Principal investigator 1 | Incyte Corporation | $2,025.00 | 09/25/2025 | Covered Recipient Teaching Hospital Tulane Medical Center | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1240489618 |
| Principal investigator 1 | Incyte Corporation | $12,973.80 | 09/25/2025 | Covered Recipient Teaching Hospital Tulane Medical Center | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kd Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1240489622 |
| Principal investigator 1 | Incyte Corporation | $3,277.00 | 07/31/2025 | Covered Recipient Teaching Hospital Tulane Medical Center | This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia. | No dispute reported | 06/30/2026 | 1240489628 |
| Principal investigator 1 | Incyte Corporation | $374.40 | 07/24/2025 | Covered Recipient Teaching Hospital Tulane Medical Center | A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kd Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib | No dispute reported | 06/30/2026 | 1240489612 |
| Principal investigator 1 | BeOne Medicines USA, Inc. | $22,678.00 | 07/14/2025 | Non-covered Recipient Entity Tulane Cancer Center | A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia | No dispute reported | 06/30/2026 | 1190332185 |
| Principal investigator 1 | Acerta Pharma LLC | $247.50 | 05/28/2025 | Non-covered Recipient Entity TULANE UNIVERSITY SCHOOL OF MEDICINE | A Randomized, Multicentre, Open-Label, Phase 3 Study to Compare Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator Choice of Chemoimmunotherapy in Subjects with Previously Untreated CLL Without del(17p) or TP53 Mutation | No dispute reported | 06/30/2026 | 1185553868 |
| Principal investigator 1 | KYOWA KIRIN, INC. | $979.85 | 05/09/2025 | Non-covered Recipient Entity TULANE UNIVERSITY CANCER CENTER | OPEN-LABEL, PHASE 2 STUDY TO ASSESS THE SAFETY OF MOGAMULIZUMAB GIVEN EVERY 4 WEEKS FOLLOWING INDUCTION IN PARTICIPANTS WITH RELAPSED/REFRACTORY CUTANEOUS T-CELL LYMPHOMA (CTCL) | No dispute reported | 06/30/2026 | 1221805271 |
| Principal investigator 1 | Incyte Corporation | $79.90 | 02/21/2025 | Covered Recipient Teaching Hospital Tulane Medical Center | A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma | No dispute reported | 06/30/2026 | 1240489603 |
| Principal investigator 1 | Incyte Corporation | $249.50 | 02/21/2025 | Covered Recipient Teaching Hospital Tulane Medical Center | A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma | No dispute reported | 06/30/2026 | 1240489608 |